Fulgent Genetics Announces Full Abstract Publication of FID-007 Combination Therapy in Head and Neck Cancer at ASCO 2026
Fulgent Genetics, a technology-driven life sciences company with established laboratory services and an expanding therapeutic development division, announced that the full abstract for its investigational cancer therapy FID-007 has been published on the official ASCO 2026 website. The data will also be presented during the Head and Neck Cancer Track in the Rapid Oral Abstract Session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The presentation is scheduled for June 1, 2026, from 4:30 p.m. to 6:00 p.m. CDT at McCormick Place, Hall D1. The abstract highlights interim clinical findings from an ongoing Phase 2 study evaluating FID-007 in combination with cetuximab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Study Background and Design
The abstract, titled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020,” reports data from a randomized, open-label Phase 2 clinical trial (NCT06332092). The study was designed to evaluate multiple aspects of FID-007, including efficacy across different dosing regimens, pharmacokinetics (PK), and overall safety and tolerability when administered alongside cetuximab.
Patients enrolled in the study had disease progression following prior treatment with PD-1-based immune checkpoint inhibitors, a population known to have limited treatment options and poor outcomes. The trial included two dosing arms to better understand optimal therapeutic exposure and to compare clinical performance between different regimen intensities.
As of the data cut-off date of December 20, 2025, FID-007 demonstrated encouraging clinical activity in combination with cetuximab, alongside a manageable and generally favorable safety profile.
Clinical Efficacy Results
The interim efficacy data presented in the abstract suggest that the combination of FID-007 and cetuximab shows promising anti-tumor activity in a difficult-to-treat patient population.
Among 42 patients evaluable for efficacy, the objective response rate (ORR) was 60% overall. This response was consistent across both treatment arms, with 58% ORR observed in Arm A and 61% ORR in Arm B. These results are particularly notable given that recurrent or metastatic head and neck squamous cell carcinoma is associated with low response rates under current standard therapies.
The median progression-free survival (mPFS) for the combined population was 7.2 months. When analyzed by treatment arm, Arm A showed a median PFS of 6.7 months, with a 95% confidence interval ranging from 2.0 to 12.8 months. Arm B demonstrated a median PFS of 7.2 months, with a confidence interval of 4.0 months to not reached (NR), indicating that some patients remained progression-free at the time of analysis.
In addition, the median duration of response (DoR) was reported at 7.4 months across the study population. Both Arm A and Arm B demonstrated similar response durability, with Arm A also reporting a median DoR of 7.4 months, while Arm B data were not yet fully mature at the time of cutoff. Importantly, 56% of responders—14 out of 25 patients—were still maintaining their response at the time of data analysis, suggesting sustained clinical benefit in a significant subset of patients.
Overall survival (OS) data remain immature, and longer follow-up will be required to fully evaluate the long-term benefit of this combination therapy.
Safety and Tolerability Profile
The safety data reported in the abstract indicate that FID-007 in combination with cetuximab has a generally manageable safety profile, with most treatment-related adverse events (TRAEs) classified as Grade 1 or Grade 2 in severity.
The most commonly observed Grade 3–4 treatment-related adverse events included hematologic and dermatologic toxicities. Specifically, neutropenia was reported in 3 patients in Arm A and 5 patients in Arm B. Anemia was observed in 2 patients in Arm A and 4 patients in Arm B. Leukopenia occurred in 3 patients, all within Arm B.
Skin-related toxicities, which are commonly associated with cetuximab-based regimens, were also observed. Acneiform dermatitis was reported in 2 patients in Arm A, while maculopapular rash and other rash-related events were reported in 2 patients in Arm B.
Importantly, there was one Grade 5 treatment-related adverse event reported in the study: a case of pneumonia in Arm B. While serious, this event appears to be isolated within the dataset presented in the abstract.
Overall, the safety profile is described as consistent with expectations for combination therapies involving targeted agents and supports continued clinical evaluation of FID-007 in this patient population.
Clinical Context and Unmet Need
Head and neck squamous cell carcinoma (HNSCC) represents a significant global health burden. According to estimates provided by Fulgent Genetics, approximately 73,000 new cases are diagnosed annually in the United States, while around 930,000 cases occur worldwide each year. A substantial proportion of these cases—between 50% and 60%—progress to recurrent or metastatic disease.
Patients with recurrent or metastatic HNSCC face particularly poor outcomes, especially after progression on immune checkpoint inhibitors such as PD-1-based therapies. Current standard-of-care options offer limited efficacy, with historical objective response rates ranging between 5.8% and 19.1%, and median progression-free survival typically between 2.3 and 3.7 months.
Against this backdrop, the reported 60% ORR and 7.2-month median PFS for FID-007 combined with cetuximab represent a meaningful improvement over existing treatment benchmarks, though further randomized studies will be required to validate these findings.
Company Perspective
Dr. Ray Yin, Co-Founder and President of Fulgent Pharma, commented on the significance of the findings and the broader unmet need in head and neck cancer treatment. He highlighted the large global patient population affected by HNSCC and emphasized the limited effectiveness of current treatment standards in the recurrent and metastatic setting.
He noted that despite advances in immunotherapy, a significant proportion of patients still experience disease progression, underscoring the need for more effective treatment combinations. Based on historical outcomes, Dr. Yin pointed out that existing therapies typically yield low response rates and short progression-free survival durations, reinforcing the potential clinical value of new approaches such as FID-007.
Fulgent expressed optimism about the ongoing development of the therapy and its potential role in improving outcomes for patients with limited treatment options.
Fulgent Genetics is a diversified biotechnology company operating across both diagnostic and therapeutic domains. Its laboratory services business provides a broad range of technical testing services, along with professional interpretation of laboratory results delivered by licensed physicians. This segment has been a core driver of the company’s operations and commercial presence.
In parallel, the company is expanding its therapeutic development pipeline, focusing on oncology drug candidates. This division leverages a proprietary nanoencapsulation and targeted delivery platform designed to enhance the therapeutic index and pharmacokinetic properties of both new and existing oncology drugs.
Fulgent’s long-term strategic vision is to transition from a primarily diagnostics-focused business into a fully integrated precision medicine company that combines diagnostic capabilities with drug development to deliver personalized cancer care solutions.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.
